Supplementary Figure – Generalizability of ORIENT-11 Trial Results to a US Standard of Care Cohort with Advanced Non-Small Cell Lung Cancer
figureposted on 2022-03-31, 07:56 authored by Figshare Future Science GroupFigshare Future Science Group, Nagasaka, Misako, Molife, Cliff, Cui, Zhanglin, Stefanik, Victoria, Li, Xiaohong, Kim, Sangmi, Lee, Hsiu-Yung, Beyrer, Julie, Blumenschein, G
Supplementary Figure 1. Patient attrition.
Abbreviations: 1L, first line therapy; ALK, anaplastic lymphoma kinase; CNS, central nervous system; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitors; aNSCLC, advanced non-small cell lung cancer
a Index date = start date of first line therapy pembrolizumab + pemetrexed + platinum
b Positive result at any time